Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MLYCD | O95822 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841879 | 0.92 | RAB9A (0.59) | NPC1RAB9AMLYCDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4158879 | 0.80 | NPC1 (0.66) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL3225126 | 0.77 | NPC1 (1.00) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL6836982 | 0.77 | ESR1 (0.48) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL10674580 | 0.77 | NPC1 (0.69) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL9422525 | 0.76 | HSP90AA1 (0.91) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL2956025 | 0.76 | NPC1 (0.68) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL29817934 | 0.76 | NPC1 (0.84) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL4930583 | 0.74 | NPC1 (0.64) | NPC1RAB9APOLBHSP90AA1KDM4E | |
| SCHEMBL28905659 | 0.74 | NPC1 (1.00) | NPC1RAB9APOLBHSP90AA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063785-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6635786-B2 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020132852-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063785-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | PARG, PARP1, PARP11 | NPC1 969/4885RAB9A 2581/4885POLB 681/4885 |
| US-20020132852-A1 | Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use | PARG, PARP1, PARP11 | NPC1 969/4885RAB9A 2581/4885POLB 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.